Skye Bioscience (SKYE) Research & Development (2014 - 2026)
Skye Bioscience (SKYE) posted quarterly Research & Development of $7.9 million for Q1 2026, up 10.26% year-over-year from $7.2 million in Q1 2025, and down 30.81% quarter-over-quarter from $11.5 million in Q4 2025.
Skye Bioscience (SKYE) Research & Development (2014 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Research & Development for 13 consecutive years, with $7.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 10.26% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $43.1 million (up 79.94% YoY), while the FY2025 annual figure was $42.4 million, up 126.51% from the prior year.
- Research & Development retreated to $7.9 million in Q1 2026 per SKYE's latest filing, from $11.5 million in the prior quarter.
- Across five years, Research & Development topped out at $14.3 million in Q2 2025 and bottomed at $1.2 million in Q1 2023.
- Historically, Research & Development has averaged $4.8 million across 5 years, with a median of $1.9 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development soared 443.65% — and 2023, when it dropped 29.58%.
- Skye Bioscience's Research & Development stood at $1.5 million in 2022, then grew by 3.53% to $1.6 million in 2023, then jumped by 389.68% to $7.8 million in 2024, then soared by 47.17% to $11.5 million in 2025, then sank by 30.81% to $7.9 million in 2026.
- Business Quant data shows SKYE's Research & Development at $7.9 million in Q1 2026, $11.5 million in Q4 2025, and $9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | 3.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.94 Mn |
| Dec 31, 2025 | 11.47 Mn |
| Sep 30, 2025 | 9.36 Mn |
| Jun 30, 2025 | 14.34 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Dec 31, 2024 | 7.79 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Jun 30, 2024 | 4.08 Mn |
| Mar 31, 2024 | 1.95 Mn |
| Dec 31, 2023 | 1.59 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 1.79 Mn |
| Mar 31, 2023 | 1.18 Mn |
| Dec 31, 2022 | 1.54 Mn |
| Sep 30, 2022 | 1.78 Mn |
| Jun 30, 2022 | 1.43 Mn |
| Mar 31, 2022 | 1.27 Mn |
| Dec 31, 2021 | 1.11 Mn |
| Sep 30, 2021 | 327,731.00 |
| Jun 30, 2021 | 880,672.00 |